However, since all patients with ATRX variants presented with aggressive/metastatic disease despite initially presenting with PCC (low metastatic risk) and VHL or FH variants (low-moderate metastatic risk), we speculate, as others, that ATRX variants contribute to metastatic risk (23). Here, ATRX is linked to adrenal gland pheochromocytoma.